Evidence map›Paper›PMID 9862247›Full record

ArticleBritish journal of clinical pharmacology1998

Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors.

J Longmore, Z Razzaque, D Shaw, A P Davenport, J Maguire, J D Pickard, W N Schofield, R G Hill

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in British journal of clinical pharmacology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2010
    Review
  7. Acute and prophylactic treatments for migraine: present and future.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2008
    Review
  8. Review
  9. Article
  10. Rizatriptan in the treatment of migraine.Neuropsychiatric disease and treatment · 2006
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

J LongmoreMerck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Eastwick Road, Harlow, Essex, UK.
Z Razzaque
D Shaw
A P Davenport
J Maguire
J D Pickard
W N Schofield
R G Hill
MSD (UK) Limited (United Kingdom) · GBAddenbrooke's Hospital · GB

Funding

Medical Research Council G9439390
6 · The paper itself

Abstract

aimsWe compared the vasoconstrictor effects of 5-HT with those of the selective 5-HT1B/1D-receptor agonists sumatriptan and rizatriptan in human isolated cranial (middle meningeal) arteries. In addition selective 5-HT1B- or 5-HT1D-receptor antibodies were used in combination with semiquantitative immunohistochemical techniques to compare the levels of expression of these receptors in human middle meningeal and coronary arteries.

methodsMiddle meningeal and coronary arteries were obtained (with consent) from either neurosurgical patients or donor hearts, respectively. Segments of middle meningeal artery were mounted in organ baths for isometric recording and cumulative concentration-effect curves to 5-HT, rizatriptan and sumatriptan were obtained. Frozen fresh sections of middle meningeal and coronary arteries were subjected to standard immunohistochemical techniques using specific 5-HT1B- or 5-HT1D-receptor primary antibodies and a radiolabelled secondary antibody. Data were subjected to analysis of variance (ANOVA) and nonlinear regression analysis.

results5-HT, rizatriptan and sumatriptan were potent vasoconstrictors in human isolated middle meningeal artery (EC50 values=32, 90 and 71 nM, respectively). A significantly higher level of 5-HT1B-receptor immunoreactivity was detected in middle meningeal artery compared with coronary artery (ANOVA, F=7.95, DF=1,4, P<0.05).

conclusionsRizatriptan and sumatriptan act selectively to cause vasoconstriction in human isolated middle meningeal artery and are 10-fold more potent than in human coronary artery. The higher level of expression of 5-HT1B-receptors in middle meningeal compared with coronary artery provides a pharmacological basis for the craniovascular selectively of both rizatriptan and sumatriptan.

Indexed as

AdultAgedAged, 80 and overCoronary VesselsFemaleHumansImmunohistochemistryIn Vitro TechniquesMaleMeningeal ArteriesMiddle AgedReceptor, Serotonin, 5-HT1BReceptor, Serotonin, 5-HT1DReceptors, SerotoninSumatriptanTriazolesHTR1B protein, humanReceptor, Serotonin, 5-HT1BReceptor, Serotonin, 5-HT1DReceptors, SerotoninrizatriptanSumatriptanTriazolesTryptaminesVasoconstrictor Agents

Identifiers

PMID9862247
PMCPMC1873795
OpenAlexW1549883691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.